Amylin, Eastbourne claim victory following company's annual meeting

By Lisa Kerner

Charlotte, N.C., May 27 - Amylin Pharmaceuticals, Inc. said based on preliminary election results, no more than two of the five dissident nominees were elected to the company's board of directors on Wednesday.

Shareholders voted to elect at least 10 of Amylin's nominees, including new independent nominees Paul N. Clark and Paulo F. Costa, an Amylin news release said.

Eastbourne Capital Management, LLC said that based on voting estimates from its proxy solicitor, MacKenzie Partners, Inc., both Eastbourne and Carl Icahn have succeeded in electing one nominee to the Amylin board.

IVS Associates, Inc., the independent inspector of elections, is expected to issue preliminary results early next week, according to Amylin, with final certified results to be announced.

Amylin is a San Diego biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.